Description: Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.

Description: If you are wondering whether Biogen’s current share price still offers value, or if the recent run has already priced in the good news, this article is for you. Biogen closed at US$185.63, with returns of 1.7% over 7 days, 6.6% over 30 days, 4.4% year to date, and 29.8% over 1 year. However, the 3-year and 5-year returns of 35.9% and 32.2% declines tell a different story for longer term holders. Recent news flow around Biogen has centered on its position in pharmaceuticals and biotech and on...

Description: The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW

Description: Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.

Description: Biogen (NASDAQ:BIIB) CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its cost structure. Speaking in a JPMorgan session moderated by analyst Chris Schot

Description: Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people living with SMA CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted ma

Description: BEDFORD, Mass., January 11, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR

Description: Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to $190 from $142 but maintained a Hold rating, telling investors in a research note that while it updated its model, the fundamental views remain […]

Description: Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it into formal review in China. This step could broaden access to Alzheimer’s treatment by shifting some care from hospital infusion centers to self-administered therapy, potentially easing pressure on healthcare systems in a rapidly aging market. Next, we’ll examine how the China review for at-home...

Description: Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s current valuation and risk reward profile. See our latest analysis for Biogen. The LEQEMBI milestone lands at a time when Biogen’s 90 day share price return of 15.67% contrasts with a flat year to date share price picture and a mixed longer history, with a 1 year total shareholder return of 14.03% but...

Description: If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) f

Description: Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.

Description: Byooviz received approval from the European Commission in August 2021 as a single-use intravitreal vial.

Description: INCHEON, Korea, January 02, 2026--Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe.

Description: Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.

Description: Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.

Description: In recent days, Biogen has reported long-term Phase 3 and extension data showing its ALS therapy QALSODY can slow SOD1-ALS progression and, in some cases, help patients regain lost function, while the company was also removed from the Nasdaq-100 index. At the same time, mixed analyst views now center on how QALSODY’s data, Biogen’s Alzheimer’s drug Leqembi, and its emerging multiple sclerosis pipeline might reshape the company’s future earnings mix as it adapts to index removal. We’ll now...

Description: Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, something not previously reported in the natural history of SOD1-ALSBiogen is committed to advancing additional ALS research, including the ongoing QALSODY ATLAS study in pre-symptomatic SOD1-ALS and a robust discovery pipeline in ALS CAMBRIDGE, Mass., Dec

Description: Shares of biotech company Biogen (NASDAQ:BIIB) jumped 2.8% in the morning session after RBC Capital reiterated an "Outperform" rating and a $210 price target on the stock, naming it a top large-cap pick for 2026.

Description: Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...

Description: We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, citing concerns that BIIB’s reliance on royalty streams and challenges in its core business could weigh on future earnings and […]

Description: MSTR was being eyed for possible Nasdaq-100 removal, but when the index reconstitutes next week, it will get to stay. Other companies, including Biogen and Lululemon, will be removed.

Description: Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.

Description: Michael Saylor's Bitcoin (BTC) treasury company, Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, has been successful in retaining its spot in the Nasdaq 100 (NDQ). A benchmark stock market index in the U.S., the Nasdaq 100 tracks hundred of the largest non-financial ...

Description: Annual rebalancing brings shifts across major tech and growth names

Description: Seagate, Western Digital lead a stunning reshuffle as tech laggards like Lululemon and Trade Desk get the boot.

Description: Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on ​Friday, continuing its year-long stint in the benchmark ‌at a time where analysts have raised questions over its business ‌model. Some market watchers have suggested Strategy's pioneering business model of buying-and-holding bitcoin, which has spawned dozens of copycats, more closely resembles that of an investment fund. Nasdaq said Biogen, ‍CDW Corporation, Globalfoundries, Lululemon Athletica, On Semiconductor and Trade Desk were removed from the tech-heavy exchange's benchmark index.

Description: Bitcoin hoarding giant Strategy may be at risk of being removed from the Nasdaq 100 index at its annual reshuffle on Friday, amid questions over its business model that have weighed ​on its share price, some analysts flagged this week. After a sizzling rally that pushed its market capitalization to a peak of $128 billion earlier this ‌year, Strategy - which started out as software company MicroStrategy but pivoted to bitcoin investing in 2020 - was included last December under the index's technology sub-category. Strategy reported a net profit of $2.78 billion for the three months ended September 30, compared with a loss of $340.2 million a year earlier, mostly driven by an accounting change that allowed it to book gains on its bitcoin holdings.

Description: Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift reflects a cautiously constructive Street narrative that balances near term execution risks with growing confidence in longer term drivers such as Leqembi, the core neurology franchise, and late stage pipeline assets. Stay tuned to learn how you can track these evolving assumptions and the...

Description: If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the numbers are really saying. The stock has climbed 13.6% over the last month and is up 18.4% year to date, even though it is still down sharply over 3 and 5 years. That hints at a possible shift in how the market is reassessing its long term prospects and risk profile. Recent headlines have...

Description: AbbVie and Genmab’s Epkinly triplet is poised to become a new standard of care for FL.

Description: Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls

Description: Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a “hawkish rate cut.” Where they do cut 25 basis ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More

Description: GREENWICH, Conn. & LJUBLJANA, Slovenia, December 10, 2025--Great Point Partners ("GPP" or "the Firm"), a Greenwich-based private investment firm focused exclusively on the healthcare industry, today announced that it has acquired a majority stake in Lenis Group ("Lenis" or "the Company"), a fast-growing Slovenian-based full-service regional commercialization and distribution partner for niche and specialty Rx medicines in Central and Eastern Europe ("CEE").

Description: Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank refreshed its 2026 sector outlook.

Description: TORONTO, December 09, 2025--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive symptoms, with benefits seen in clinical studies as early as day 3, significant reduction of symptoms by t

Description: TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National He

Description: Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.

Description: Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.

Description: In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet syndrome and oral macrocyclic peptide research, including positive updates on lecanemab’s subcutaneous formulation and zorevunersen’s long-term effects. The latest findings suggest Biogen is deepening its presence in high-need neurological conditions with therapies that aim not only to relieve...

Description: Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: BEDFORD, Mass. & CAMBRIDGE, Mass., December 05, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES

Description: —Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and c

Description: Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States TOKYO and CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tok

Description: Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record. In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp. The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.

Description: Biogen (BIIB) shares have been actively discussed lately, as some investors weigh the stock's longer-term track record against recent performance. Over the past month, Biogen stock has climbed by 15%, which is higher compared to its returns from earlier periods. See our latest analysis for Biogen. Momentum has picked up for Biogen lately, with a 15% one-month share price return and year-to-date gains of 18%, signaling renewed optimism after a tough few years. Still, its 1-year total...

Description: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The findin

Description: INCHEON, Korea, December 02, 2025--Samsung Bioepis' Byooviz PFS gains European approval.

Description: New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modificationCAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today annou

Description: BEDFORD, Mass. & CAMBRIDGE, Mass., December 01, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.

Description: If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for

Description: Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around policy headwinds and progress in the company’s drug pipeline. Stay tuned to discover how investors can monitor these evolving narratives as market sentiment shifts. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Biogen. What Wall...

Description: The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.

Description: Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.

Description: BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.

Description: LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha

Description: Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.

Description: The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car

Description: A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.

Description: Investing.com -- Biogen shares could benefit from Novo Nordisk’s Phase III Evoke/Evoke+ trials failure, according to analysts at Jefferies.

Description: Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop or

Description: TORONTO & CAMBRIDGE, Mass., November 24, 2025--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.

Description: Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."

Description: In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q spinal muscular atrophy, with a final European Commission decision expected by January 2026. This regulatory progress not only has the potential to expand treatment options for SMA patients in Europe but also strengthens Biogen’s position within the neurological disease treatment market. We'll...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: November has been NO-vember when it comes to tech stocks. Investors are shunning artificial-intelligence leaders and other momentum names. Investors seem to be embracing drug stocks, insurers, and medical equipment companies again.

Description: New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at th

Description: FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.

Description: Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, despite currently available therapies. See our latest analysis for Biogen. Biogen’s share price has gained real momentum in recent weeks, climbing 15.2% in the past month and 18.6% over the last 90 days, after a prolonged period of lackluster returns. Despite a recent flurry of product news and...

Description: The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio

Description: Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Description: – Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera

Description: BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent

Description: ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.

Description: Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human

Description: CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and access

Description: TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare product

Description: DelveInsight's Antibody-mediated Rejection Market Insights report includes a comprehensive understanding of current treatment practices, antibody-mediated rejection emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: Biogen recently reported third quarter 2025 earnings results that surpassed expectations, with revenue rising to US$2.53 billion and net income increasing to US$466.5 million compared to a year ago, fueled by strong sales from newly launched therapies such as LEQEMBI, SKYCLARYS, and ZURZUVAE. This performance helped offset declines in Biogen's established multiple sclerosis franchise and prompted renewed analyst confidence in the company’s evolving drug portfolio. We'll explore how Biogen’s...

Description: Wondering if Biogen stock is priced for opportunity or risk? You are not alone. There is a lot more beneath the surface to consider when assessing its true value. Recently, Biogen’s share price has seen a modest climb, up 4.8% over the past week and 3.0% in the last month. However, it is still down 9.9% over the past year, pointing to both shifting expectations and evolving market sentiment. Several headlines have caught investor attention, including new clinical trial partnerships and...

Description: Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls

Description: Pre-Market Futures: The futures are trading modestly higher on Thursday after a big snap-back rally on Wednesday, as all the major indices staged a solid rebound following the Tuesday sell-off. While some of the buying was likely “Buy the Dip” investors doing what has come naturally for the last three years, another possible tailwind was ... Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More

Description: Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.

Description: Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple sclerosis portfolio. Management attributed much of the growth to LEQEMBI, SKYCLARYS, and ZURZUVAE, which together posted significant year-on-year gains. CEO Christopher Viehbacher highlighted that “launch products again in this quarter, and if I look at this year-to-date as well, more than have offset th

Description: The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

Description: Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potentialExhibitor Spotlight to discuss role of CD38 cells across a range of immune-mediated kidney diseasesFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated

Description: Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.

Description: Biogen (BIIB) delivered a notable turnaround this year, posting EPS growth of 32.1% after five years of average annual declines of 20.5%. Net profit margins improved to 15.3% from last year’s 12%. Forecasts now call for earnings to grow at 7.3% per year, even as revenue is expected to decline at a 0.8% annual rate over the next three years. With shares trading at $149.61, well below the estimated fair value of $333.62 and a price-to-earnings ratio of 14.3x compared to the industry average of...

Description: Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest analysis for Biogen. While Biogen’s share price has dipped nearly 3% over the past month, the bigger picture shows momentum has faded, with a 90-day share price return of over 13% but a disappointing 1-year total shareholder return of -14%. That mix of short-term growth and long-term declines...

Description: Biogen Inc (BIIB) reports robust financial performance with significant growth in launch products and a focus on expanding its pipeline for future success.

Description: Two of Biogen's key growth drivers hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down slightly.

Description: Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.

Description: Biogen stock’s consensus analyst price target has ticked up slightly, moving from $172.34 to $172.55. This adjustment reflects fresh optimism around the company’s growth prospects, as well as nuanced shifts in both bullish and bearish analyst outlooks. Investors will want to follow closely to understand how changing views and upcoming catalysts could continue shaping Biogen’s story in the months ahead. Stay updated as the Fair Value for Biogen shifts by adding it to your watchlist or...

Description: Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.

Description: While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.

Description: Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer’s drug and rare-disease treatments.

Description: Biogen (BIIB) delivered earnings and revenue surprises of +23.65% and +8.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell 2.6% after the biotech company cut its full-year earnings guidance despite reporting better-than-expected third quarter results, with adjusted earnings and revenue surpassing analyst estimates.

Description: BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 117.2 million which is an increase of approximately 68 percent compared to the royalty obtained by BioArctic for the third quarter 2024.

Description: Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for.

Description: Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathologyTOKYO and CAMBRIDGE, Mass., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO

Description: Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic lupus erythematosus (SLE), supported by efficacy across multiple endpoints and promising safety data, especially in women of childbearing age. This follows a series of pipeline enhancements for Biogen in immunology and rare diseases, including a new licensing agreement with Vanqua Bio for a...

Description: The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Description: Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Description: The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a

Description: While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Description: Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: DelveInsight's Glomerulonephritis Market Insights report includes a comprehensive understanding of current treatment practices, glomerulonephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the suc

Description: Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of lifePresentation of preclinical study of DZP showing minimal to no human placental transfer CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug

Description: RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.

Description: PISCATAWAY, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- IMPALA, a global consortium dedicated to advancing digital and analytics-driven quality in biopharmaceutical development, announced the appointment of Ann Marie Dunne, Global Head of R&D Quality and Compliance at Biogen, as its new Chair. She succeeds Jonathan Taylor, Vice President and Global Head of Product Development Quality at Roche, who has served as Chair since IMPALA’s inception. Known for her ability to bridge innovation and execution,